Brief: Hansoh Pharmaceutical Says HS-10541 Tablets Obtain Clinical Trial Approval From China's NMPA
13/05/2026 16:30
May 13 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: HS-10541 TABLETS OBTAIN CLINICAL TRIAL APPROVAL FROM CHINA'S NMPA Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion